MCID: HDR002
MIFTS: 57

Hidradenitis Suppurativa

Categories: Blood diseases, Endocrine diseases, Genetic diseases, Rare diseases, Skin diseases

Aliases & Classifications for Hidradenitis Suppurativa

MalaCards integrated aliases for Hidradenitis Suppurativa:

Name: Hidradenitis Suppurativa 12 77 54 26 44 45 15 17 74
Acne Inversa 54 26 38 41
Hidradenitides, Suppurative 26
Suppurative Hidradenitides 26
Hidradenitis, Suppurative 26
Suppurative Hidradenitis 26
Acne Inversa, Familial 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2280
KEGG 38 H00681
MeSH 45 D017497
NCIt 51 C128429
SNOMED-CT 69 59393003
ICD10 34 L73.2
UMLS 74 C0162836

Summaries for Hidradenitis Suppurativa

NIH Rare Diseases : 54 Hidradenitis suppurativa (HS) is a chronic skin disease which causes painful, boil-like lumps that form under the skin and often secrete pus and blood. HS occurs most often in areas where skin rubs together, such as the armpits, groin, and under the breasts. Symptoms usually begin after puberty. The first sign may be a single pocket of pus (abscess) or hard lumps associated with hair follicles. The abscesses or lumps  often change to painful swollen clusters of skin sores that drain a bloody and often, bad smelling discharge. As the sores heal, they may leave hardened, rope-like scars or form tunnels under the skin (called sinus tracks) that can be disfiguring and make movement difficult. As time goes by, the skin lesions occur more often and get worse over time. In most cases, the cause of HS is unknown. Genetics, environment, and hormonal factors may play a role. Some cases of HS have been associated with specific genes, including NCSTN, PSEN1, and PSENEN. Diagnosis of HS is made based on the clinical symptoms. Treatment of HS is determined by the severity of the symptoms and can include topical or oral antibiotics, anti-inflammatories, other medications, and surgery. Losing weight and stopping smoking can also improve the symptoms. HS causes chronic pain, significant scarring, and can be socially isolating, but is not life-threatening. People with HS have an increased chance to feel depressed or anxious, which, along with chronic pain, may impact their quality of life.

MalaCards based summary : Hidradenitis Suppurativa, also known as acne inversa, is related to pyoderma gangrenosum and pyoderma, and has symptoms including painful nodules, pruritus and exanthema. An important gene associated with Hidradenitis Suppurativa is NCSTN (Nicastrin), and among its related pathways/superpathways are Wnt signaling pathway and Notch signaling pathway. The drugs Adalimumab and Anti-Inflammatory Agents have been mentioned in the context of this disorder. Affiliated tissues include skin, breast and thyroid, and related phenotypes are craniofacial and hematopoietic system

Disease Ontology : 12 A hidradenitis that is characterized by chronic inflammation of the apocrine sweat glands, has symptom painful nodules, abscesses, sinus tract formation, scarring, erythema, pruritis, and pain, and has material basis in chronic inflammation of the apocrine sweat glands leading to recurrent folliculitis and an accompanying immune response that worsens inflammation.

Genetics Home Reference : 26 Hidradenitis suppurativa, also known as acne inversa, is a chronic skin disease characterized by recurrent boil-like lumps (nodules) under the skin. The nodules become inflamed and painful. They tend to break open (rupture), causing abscesses that drain fluid and pus. As the abscesses heal, they produce significant scarring of the skin.

MedlinePlus : 44 Hidradenitis suppurativa (HS) is a chronic skin disease. It can occur in one or multiple areas of your body. HS usually develops in your armpits, groin, and anal area. It causes long-term skin inflammation and can be painful. Symptoms include Blackheads and red, tender bumps, called abscesses. The abscesses get bigger, break open, and leak pus Tunnels that form under the skin between abscesses Scarring No one knows what causes HS. It is more common in women, African Americans, and people who have had acne. It usually starts after the teenage years. Treatments include antibiotics, anti-inflammatory medicines, and sometimes surgery. Losing weight or wearing looser clothing may help some patients avoid skin irritation.

Wikipedia : 77 Hidradenitis suppurativa (HS), also known as acne inversa, is a long term skin disease characterized by... more...

Related Diseases for Hidradenitis Suppurativa

Diseases related to Hidradenitis Suppurativa via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 210)
# Related Disease Score Top Affiliating Genes
1 pyoderma gangrenosum 31.3 NOD2 TNF
2 pyoderma 31.3 NOD2 TNF
3 crohn's colitis 31.2 NOD2 TNF
4 spondyloarthropathy 31.0 IL17A TNF
5 inflammatory bowel disease 30.9 IL17A NOD2 TNF
6 arthritis 30.9 IL17A NOD2 TNF
7 joint disorders 30.7 IL17A TNF
8 colitis 30.5 IL17A NOD2 TNF
9 ulcerative colitis 30.5 IL17A NOD2 TNF
10 spondylarthropathy 30.4 NOD2 TNF
11 spondyloarthropathy 1 30.4 IL17A NOD2 TNF
12 spondylitis 30.4 IL17A NOD2 TNF
13 melkersson-rosenthal syndrome 30.4 NOD2 TNF
14 dowling-degos disease 30.3 DSC2 KRT14 NCSTN PSENEN
15 skin disease 30.1 IL17A KRT10 KRT14 TNF
16 alzheimer disease 30.0 NCSTN PSEN1 PSENEN TNF
17 sarcoidosis 1 30.0 IL12RB1 NOD2 TNF
18 hidradenitis 29.2 DSC2 DSG2 IL12RB1 IL17A KRT10 KRT14
19 acne inversa, familial, 1 12.0
20 perifolliculitis capitis abscedens et suffodiens, familial 11.8
21 acne inversa, familial, 2, with or without dowling-degos disease 11.7
22 papillon-lefevre syndrome 11.4
23 acne inversa, familial, 3 11.4
24 pyogenic sterile arthritis, pyoderma gangrenosum, and acne 11.4
25 neurofibromatosis, type ii 11.0
26 squamous cell carcinoma 10.9
27 crohn's disease 10.8
28 psoriasis 10.7
29 dowling-degos disease 1 10.5
30 malignant atrophic papulosis 10.5
31 pustulosis of palm and sole 10.5
32 lymphedema 10.5
33 down syndrome 10.4
34 amyloidosis 10.4
35 retinal dystrophy, iris coloboma, and comedogenic acne syndrome 10.4
36 cellulitis 10.4
37 depression 10.4
38 diabetes mellitus, noninsulin-dependent 10.4
39 cytokine deficiency 10.4
40 sebaceous gland disease 10.4 NCSTN PSENEN
41 miller fisher syndrome 10.3 PSENEN TNF
42 neutrophil migration 10.3
43 diabetes mellitus 10.3
44 sapho syndrome 10.3
45 adenocarcinoma 10.3
46 elephantiasis 10.3
47 rosacea 10.3
48 pyoderma gangrenosum-acne-suppurative hidradenitis syndrome 10.3
49 ileocolitis 10.3 NOD2 TNF
50 granulomatous dermatitis 10.3 NOD2 TNF

Graphical network of the top 20 diseases related to Hidradenitis Suppurativa:



Diseases related to Hidradenitis Suppurativa

Symptoms & Phenotypes for Hidradenitis Suppurativa

Symptoms:

12
  • painful nodules

UMLS symptoms related to Hidradenitis Suppurativa:


pruritus, exanthema

MGI Mouse Phenotypes related to Hidradenitis Suppurativa:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 craniofacial MP:0005382 9.55 IL17A KRT14 NCSTN PSEN1 TNF
2 hematopoietic system MP:0005397 9.5 IL12RB1 IL17A KRT14 NCSTN NOD2 PSEN1
3 immune system MP:0005387 9.17 IL12RB1 IL17A KRT14 NCSTN NOD2 PSEN1

Drugs & Therapeutics for Hidradenitis Suppurativa

Drugs for Hidradenitis Suppurativa (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 85)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Adalimumab Approved Phase 4,Phase 3,Phase 2 331731-18-1 16219006
2 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Not Applicable
3 Anesthetics Phase 4,Phase 1
4 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
5 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
6 Anti-Bacterial Agents Phase 3,Phase 2,Not Applicable
7 Antibiotics, Antitubercular Phase 3,Not Applicable
8 Antibodies Phase 3,Phase 2,Phase 1,Early Phase 1
9 Immunoglobulins Phase 3,Phase 2,Phase 1,Early Phase 1
10 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1,Early Phase 1
11
Apremilast Approved, Investigational Phase 2 608141-41-9 11561674
12
Etanercept Approved, Investigational Phase 2 185243-69-0
13
Ustekinumab Approved, Investigational Phase 2 815610-63-0
14
Infliximab Approved Phase 2 170277-31-3
15
Hydroxychloroquine Approved Phase 1, Phase 2 118-42-3 3652
16 Brodalumab Approved, Investigational Phase 2 1174395-19-7
17
Polyestradiol phosphate Approved Phase 2 28014-46-2
18
Estradiol Approved, Investigational, Vet_approved Phase 2 50-28-2 5757
19
Ethinyl Estradiol Approved Phase 2 57-63-6 5991
20
Drospirenone Approved Phase 2 67392-87-4 68873
21
Glutamic Acid Approved, Nutraceutical Phase 2 56-86-0 33032
22
Proline Approved, Nutraceutical Phase 2 147-85-3 145742
23 Anti-Infective Agents Phase 2,Phase 1,Not Applicable
24 Immunosuppressive Agents Phase 2,Not Applicable
25 Dermatologic Agents Phase 2,Not Applicable
26 Pharmaceutical Solutions Phase 2,Phase 1,Not Applicable
27 Hormones Phase 2,Not Applicable
28 Hormone Antagonists Phase 2,Not Applicable
29 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2,Not Applicable
30 Analgesics Phase 2
31 Analgesics, Non-Narcotic Phase 2
32 Anti-Inflammatory Agents, Non-Steroidal Phase 2
33 Angiogenesis Inhibitors Phase 2
34 Angiogenesis Modulating Agents Phase 2
35 Peripheral Nervous System Agents Phase 2,Not Applicable
36 Interleukin 1 Receptor Antagonist Protein Phase 2
37 Complement System Proteins Phase 2
38 Gastrointestinal Agents Phase 2
39 lysine Phase 2
40 Antimalarials Phase 1, Phase 2
41 Antiprotozoal Agents Phase 1, Phase 2
42 Antiparasitic Agents Phase 1, Phase 2
43 Epidiolex Phase 2
44 Olive Phase 2
45 chlorophyllin Phase 2
46 Contraceptives, Oral Phase 2
47 Mineralocorticoid Receptor Antagonists Phase 2
48 Contraceptive Agents Phase 2
49 Natriuretic Agents Phase 2
50 Drospirenone and ethinyl estradiol combination Phase 2

Interventional clinical trials:

(show top 50) (show all 76)
# Name Status NCT ID Phase Drugs
1 Cost-effectiveness of Adalimumab and Surgery vs Adalimumab in HS Recruiting NCT03221621 Phase 4 Adalimumab Injection
2 Safety and Efficacy of Humira (Adalimumab) for Hidradenitis Suppurativa (HS) Peri-Surgically (SHARPS Study) Active, not recruiting NCT02808975 Phase 4 Adalimumab;Placebo
3 Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa Completed NCT01468207 Phase 3
4 Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa Completed NCT01468233 Phase 3
5 Open-label Study of the Safety and Efficacy of Adalimumab in the Treatment of Hidradenitis Suppurativa Completed NCT01635764 Phase 3
6 Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS) Recruiting NCT03713632 Phase 3 Secukinumab
7 This is a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS). Recruiting NCT03713619 Phase 3 secukinumab
8 Effect of Sclerotherapy on Fistulas and Sinus Tracts in Hidradenitis Suppurativa Recruiting NCT02805595 Phase 3 23.4% Hypertonic saline;Saline
9 Open-label Study of Adalimumab in Japanese Subjects With Hidradenitis Suppurativa Active, not recruiting NCT02904902 Phase 3 adalimumab
10 To Determine the Efficacy of a Laser Device for the Treatment of Hidradenitis Suppurativa Terminated NCT00367328 Phase 3
11 A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa. Completed NCT03248531 Phase 2 Bimekizumab;Adalimumab
12 Efficacy, Safety, and Pharmacokinetics Study of CJM112 in Hidradenitis Suppurativa Patients Completed NCT02421172 Phase 2 Placebo
13 Single Center Study of Apremilast for the Treatment of Hidradenitis Suppurativa Completed NCT02695212 Phase 2 Apremilast
14 To Assess the Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa Completed NCT00827996 Phase 2 adalimumab
15 Anakinra as a Treatment for Hydradenitis Suppurativa Completed NCT01516749 Phase 2 anakinra
16 Studying Complement Inhibition in Patients With Moderate to Severe Hidradenitis Suppurativa Completed NCT03001622 Phase 2
17 Etanercept in Hidradenitis Suppurativa Completed NCT00329823 Phase 2 Etanercept sc 50mg per week for 12 weeks
18 Anakinra in Hidradenitis Suppurativa Completed NCT01558375 Phase 2 Water for injection;Anakinra
19 MABp1 IN HIDRADENITIS SUPPURATIVA REFRACTORY TO ADALIMUMAB Completed NCT02643654 Phase 2 MABp1;Placebo
20 A Proof of Concept Study to Evaluate the Effectiveness of Ustekinumab in Hidradenitis Suppurativa Completed NCT01704534 Phase 2 Ustekinumab
21 Short-term Safety, Efficacy and Mode of Action of Apremilast in Moderate Suppurative Hidradenitis Completed NCT03049267 Phase 2 Apremilast;Placebo Oral Tablet
22 Study of Adalimumab in Subjects With Moderate to Severe Chronic Hidradenitis Suppurativa Completed NCT00918255 Phase 2 Placebo
23 Study to Assess the Safety and Efficacy of Infliximab to Treat Hidradenitis Suppurtativa Completed NCT00795574 Phase 2 infliximab;Placebo Comparator
24 Etanercept for Treatment of Hidradenitis Completed NCT00107991 Phase 2 etanercept
25 Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa Recruiting NCT03827798 Phase 2 CFZ533;Placebo to CFZ533;LYS006;Placebo to LYS006
26 Evaluation of Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis Suppurativa Recruiting NCT03852472 Phase 2 Avacopan
27 A Study of Bermekimab in Patients With Hidradenitis Suppurativa Recruiting NCT03512275 Phase 2 Bermekimab Monoclonal Antibody 400 mg
28 A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS) Recruiting NCT03628924 Phase 2 Guselkumab dose 1;Guselkumab dose 2;Guselkumab dose 3;Placebo
29 A Placebo-Controlled Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa Recruiting NCT03607487 Phase 2 INCB054707;Placebo
30 Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS) Active, not recruiting NCT03487276 Phase 2 IFX-1;Placebo
31 A Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa Active, not recruiting NCT03569371 Phase 2 INCB054707
32 Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa Active, not recruiting NCT03275870 Phase 1, Phase 2 Hydroxychloroquine
33 A Global Study Comparing Risankizumab to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Not yet recruiting NCT03926169 Phase 2 Risankizumab;Placebo for risankizumab
34 Treatment of Moderate Hidradenitis Suppurativa Not yet recruiting NCT03910803 Phase 2 Brodalumab
35 Study to Investigate the Efficacy and Safety of Cannabis Oil for the Treatment of Subjects With Hidradenitis Suppurativa Not yet recruiting NCT03929835 Phase 2 Cannabis oil;Placebo
36 Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa Terminated NCT01838499 Phase 2
37 A Study to Examine the Safety and Efficacy of Drospirenone and Ethinyl Estradiol (YAZ) Versus Placebo In HS Terminated NCT00722800 Phase 2 drospirenone and ethinyl estradiol (YAZ);Placebo
38 Efficacy and Safety of Efalizumab in the Treatment of Moderate-Severe Hydradenitis Suppurativa Completed NCT00134134 Phase 1 efalizumab
39 Endoscopic Pilonidal Sinus Treatment With Additional Crystalized Phenol Completed NCT02277340 Phase 1
40 An Investigation Into the Efficacy of Provodine Topical Cream as Compared to 10% Benzoyl Peroxide Wash for the Treatment of Hidradenitis Suppurativa. Unknown status NCT01818167 Not Applicable 10% Benzoyl Peroxide Topical Body Wash;Provodine Topical Cream
41 Study to Compare Two Treatments for Axillary Hidradenitis Suppurativa: Carbon Dioxide Laser Versus Surgical Deroofing Unknown status NCT02163746 Not Applicable
42 Trial Comparing Efficacy of Treatments for Hidradenitis Suppurativa Unknown status NCT01063270 Not Applicable Clindamycin & Rifampin
43 Group Psychotherapy for Patients With Hidradenitis Suppurativa: Effects in Quality of Life Unknown status NCT02904408 Not Applicable
44 Patients With Hidradenitis vs Patients With Psoriasis: Psychological Impact Unknown status NCT02999698
45 Efficacy of Percutaneous Injection of Triamcinolone in the Treatment of Mammillary Fistula Unknown status NCT01315080
46 Effectiveness of Adalimumab in Moderate to Severe HidrAdenitis SuppuRativa Patients - a Multi cOuNtry studY in Real Life Setting Completed NCT02786576
47 Study on the Effect of NdYag Laser for the Treatment of Hidradenitis Suppurativa Completed NCT00494351 Not Applicable
48 A Randomized Controlled Trial Evaluating the Efficacy of Intralesional Triamcinolone in Hidradenitis Suppurativa. Completed NCT02781818 Not Applicable Triamcinolone Acetonide 10mg/mL;Triamcinolone Acetonide 40mg/mL;Normal Saline
49 Association Between Hidradenitis Suppurativa and Spondyloarthritis Completed NCT03668925 Not Applicable
50 Pilot Study on Botulinum Toxin B as Treatment for Hidradenitis Suppurativa Completed NCT03103074 Not Applicable Botulinum B Toxin

Search NIH Clinical Center for Hidradenitis Suppurativa

Cochrane evidence based reviews: hidradenitis suppurativa

Genetic Tests for Hidradenitis Suppurativa

Anatomical Context for Hidradenitis Suppurativa

MalaCards organs/tissues related to Hidradenitis Suppurativa:

42
Skin, Breast, Thyroid, Neutrophil, Testes, T Cells, Heart

Publications for Hidradenitis Suppurativa

Articles related to Hidradenitis Suppurativa:

(show top 50) (show all 1662)
# Title Authors Year
1
To what extent do disease severity and illness perceptions explain depression, anxiety and quality of life in hidradenitis suppurativa? ( 30171696 )
2019
2
Depression in Hidradenitis Suppurativa. ( 31099413 )
2019
3
The associations of depression and coping methods on health-related quality of life for those with hidradenitis suppurativa. ( 30876533 )
2019
4
Hidradenitis suppurativa and diabetes mellitus: updated systematic review and adjusted meta-analysis. ( 30730068 )
2019
5
Prevalence and Description of Hidradenitis Suppurativa in Down Syndrome: A Cross-sectional Study of 783 Subjects. ( 30460373 )
2019
6
Non-Pharmacologic Approaches for Hidradenitis Suppurativa - A Systematic Review. ( 31106609 )
2019
7
E-cadherin and p120ctn protein expression are lost in hidradenitis suppurativa lesions. ( 31107992 )
2019
8
Hidradenitis Suppurativa and Botulinum Toxin Type a Therapy: Two Cases. ( 30693648 )
2019
9
Association Between Hidradenitis Suppurativa and Lymphoma. ( 30698627 )
2019
10
Biologics for hidradenitis suppurativa: an update. ( 30702012 )
2019
11
Could isotretinoin flare hidradenitis suppurativa? A case series. ( 30719727 )
2019
12
Abstracts of the 8th European Hidradenitis Suppurativa Foundation (EHSF) Conference, 6-8 February 2019, Wrocław, Poland. ( 30723943 )
2019
13
Interrater agreement and reliability of outcome measurement instruments and staging systems used in hidradenitis suppurativa. ( 30724351 )
2019
14
Preoperative Ultrasound for Evaluation of Hidradenitis Suppurativa. ( 30726198 )
2019
15
Overall and subgroup prevalence of pyoderma gangrenosum among patients with hidradenitis suppurativa: A population-based analysis in the United States. ( 30738122 )
2019
16
Secukinumab and hidradenitis suppurativa: Friends or foes? ( 30740502 )
2019
17
Understanding the long diagnostic delay for hidradenitis suppurativa: a national survey among French general practitioners. ( 30761989 )
2019
18
Response to "Korean gender differences in hidradenitis suppurativa: nature or nurture?" ( 30767325 )
2019
19
Hidradenitis Suppurativa as a Systemic Disease: Association With Metabolic Syndrome. ( 30797524 )
2019
20
Exophytic Mass Arising Within Hidradenitis Suppurativa: Answer. ( 30801344 )
2019
21
Open-label, Investigator-Initiated, Single Site Exploratory Trial Evaluating Secukinumab, an anti IL17A monoclonal antibody, for Patients with Moderate-to-Severe Hidradenitis Suppurativa. ( 30801662 )
2019
22
Virulent Staphylococcus lugdunensis with limited genetic diversity in hidradenitis suppurativa lesions. ( 30801776 )
2019
23
Exophytic Mass Arising Within Hidradenitis Suppurativa: Challenge. ( 30802225 )
2019
24
Isotretinoin and Hidradenitis Suppurativa. ( 30802991 )
2019
25
Hidradenitis Suppurativa and Diabetes: Big Data Bias Masks a True Association. ( 30802992 )
2019
26
Combination hyperbaric oxygen therapy and ustekinumab for severe hidradenitis suppurativa. ( 30805965 )
2019
27
Apremilast for the Treatment of Mild-to-Moderate Hidradenitis Suppurativa in a Prospective, Open-Label, Phase 2 Study ( 30811140 )
2019
28
Effectiveness, safety and tolerability of drainage and punch-trocar-assisted cryoinsufflation (cryopunch) in the treatment of inflammatory acute fluid collections in hidradenitis suppurativa patients. ( 30811686 )
2019
29
Reply to: "Could Isotretinoin flare Hidradentis suppurativa? A Case Series". ( 30816560 )
2019
30
Squamous carcinoma over perineal hidradenitis suppurativa. ( 30825999 )
2019
31
Transcriptome patterns in hidradenitis suppurativa: support for the role of antimicrobial peptides and interferon pathways in disease pathogenesis. ( 30828847 )
2019
32
A new Th-17 cytokine in hidradenitis suppurativa: antimicrobial and pro-inflammatory role of IL-26. ( 30829398 )
2019
33
Hidradenitis Suppurativa (Hurley I/II): Serial Excisions with Primary Wound Closure Under Local Anesthesia As Most Adequate Treatment Approach. ( 30834010 )
2019
34
Association Between Hidradenitis Suppurativa and Metabolic Syndrome. ( 30846164 )
2019
35
Topical, systemic and biologic therapies in hidradenitis suppurativa: pathogenic insights by examining therapeutic mechanisms. ( 30854183 )
2019
36
Commentary: Hidradenitis Suppurativa: A Systematic Review Integrating Inflammatory Pathways Into a Cohesive Pathogenic Model. ( 30858850 )
2019
37
North American Clinical Management Guidelines for Hidradenitis Suppurativa: a Publication from the United States and Canadian Hidradenitis Suppurativa Foundations. Part II: Topical, Intralesional, and Systemic medical Management. ( 30872149 )
2019
38
Comment on "Interruption of oral clindamycin plus rifampicin therapy in patients with hidradenitis suppurativa: an observational study to assess prevalence and causes". ( 30872151 )
2019
39
Reply to "Comment on 'Interruption of oral clindamycin plus rifampicin therapy in patients with hidradenitis suppurativa: an observational study to assess prevalence and causes' ". ( 30872153 )
2019
40
North American Clinical Management Guidelines for Hidradenitis Suppurativa: a Publication from the United States and Canadian Hidradenitis Suppurativa Foundations. Part I: Diagnosis, Evaluation, and the use of Complementary and Procedural Management. ( 30872156 )
2019
41
Lack of photographic documentation undermines assessment of hidradenitis suppurativa phenotypes. ( 30874297 )
2019
42
Assessing the Efficacy of New Biologic Therapies in Hidradenitis Suppurativa Consistency vs Bias in Outcome Measures in Moderate and Severe Disease. ( 30875132 )
2019
43
Reply to comment: guselkumab in the treatment of severe hidradenitis suppurativa. ( 30875137 )
2019
44
Mast cells in hidradenitis suppurativa: a clinicopathological study. ( 30877368 )
2019
45
Treatment of Hidradenitis Suppurativa with Extensive Resection of the Lesion and Coverage with Perforator Flaps of the Lateral Thoracic Wall (Lateral Thoracic Artery, Thoracodorsal Artery Perforators). ( 30881834 )
2019
46
Hidradenitis Suppurativa: Estimated Prevalence, Clinical Features, Concomitant Conditions, and Diagnostic Delay in a University Teaching Hospital in Buenos Aires, Argentina. ( 30885385 )
2019
47
Commentary on Squamous Cell Carcinoma in Perineal, Perianal, and Gluteal Hidradenitis Suppurativa: Experience in 12 Patients. ( 30893153 )
2019
48
Defining Fistular Patterns in Hidradenitis Suppurativa: Impact in the Management. ( 30893168 )
2019
49
Metformin use in hidradenitis suppurativa. ( 30893570 )
2019
50
Patient Perspectives: What is hidradenitis suppurativa (HS)? ( 30895674 )
2019

Variations for Hidradenitis Suppurativa

Expression for Hidradenitis Suppurativa

Search GEO for disease gene expression data for Hidradenitis Suppurativa.

Pathways for Hidradenitis Suppurativa

Pathways related to Hidradenitis Suppurativa according to KEGG:

38
# Name Kegg Source Accession
1 Wnt signaling pathway hsa04310
2 Notch signaling pathway hsa04330
3 Neurotrophin signaling pathway hsa04722

Pathways related to Hidradenitis Suppurativa according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.01 DSC2 DSG2 KRT10 KRT14 NCSTN PSENEN
2
Show member pathways
12.32 IL12RB1 IL17A NOD2 TNF
3
Show member pathways
12.19 DSC2 DSG2 KRT10 KRT14
4 11.98 NCSTN PSEN1 PSENEN
5
Show member pathways
11.94 NCSTN PSEN1 PSENEN
6 11.84 NCSTN PSEN1 PSENEN
7
Show member pathways
11.78 IL12RB1 IL17A TNF
8 11.54 IL12RB1 IL17A TNF
9
Show member pathways
11.4 NCSTN PSEN1 PSENEN
10 11.24 NCSTN PSEN1 PSENEN
11 11.06 IL17A TNF
12 10.99 NCSTN PSEN1 PSENEN
13 10.89 NOD2 TNF
14 10.49 NCSTN PSEN1 PSENEN
15 10.07 PSEN1 PSENEN
16 10.03 NCSTN PSEN1 PSENEN

GO Terms for Hidradenitis Suppurativa

Cellular components related to Hidradenitis Suppurativa according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.56 DSG2 NOD2 PSEN1 TNF
2 desmosome GO:0030057 9.16 DSC2 DSG2
3 cornified envelope GO:0001533 9.13 DSC2 DSG2 KRT10
4 gamma-secretase complex GO:0070765 8.8 NCSTN PSEN1 PSENEN

Biological processes related to Hidradenitis Suppurativa according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 Notch signaling pathway GO:0007219 9.74 NCSTN PSEN1 PSENEN
2 keratinization GO:0031424 9.73 DSC2 DSG2 KRT10 KRT14
3 positive regulation of catalytic activity GO:0043085 9.69 NCSTN PSEN1 PSENEN
4 cornification GO:0070268 9.67 DSC2 DSG2 KRT10 KRT14
5 positive regulation of MAP kinase activity GO:0043406 9.65 NOD2 PSEN1 TNF
6 protein processing GO:0016485 9.63 NCSTN PSEN1 PSENEN
7 regulation of heart rate by cardiac conduction GO:0086091 9.61 DSC2 DSG2
8 positive regulation of interleukin-8 production GO:0032757 9.6 NOD2 TNF
9 regulation of synaptic transmission, glutamatergic GO:0051966 9.59 PSEN1 TNF
10 positive regulation of osteoclast differentiation GO:0045672 9.58 IL17A TNF
11 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.58 IL17A NOD2
12 membrane protein ectodomain proteolysis GO:0006509 9.58 NCSTN PSEN1 PSENEN
13 amyloid-beta metabolic process GO:0050435 9.56 NCSTN PSEN1
14 epithelial cell proliferation GO:0050673 9.55 NCSTN PSEN1
15 regulation of ventricular cardiac muscle cell action potential GO:0098911 9.54 DSC2 DSG2
16 astrocyte activation GO:0048143 9.52 PSEN1 TNF
17 amyloid precursor protein metabolic process GO:0042982 9.5 NCSTN PSEN1 PSENEN
18 bundle of His cell-Purkinje myocyte adhesion involved in cell communication GO:0086073 9.49 DSC2 DSG2
19 Notch receptor processing GO:0007220 9.43 NCSTN PSEN1 PSENEN
20 amyloid precursor protein catabolic process GO:0042987 9.33 NCSTN PSEN1 PSENEN
21 Notch receptor processing, ligand-dependent GO:0035333 9.13 NCSTN PSEN1 PSENEN
22 amyloid-beta formation GO:0034205 8.8 NCSTN PSEN1 PSENEN

Molecular functions related to Hidradenitis Suppurativa according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell adhesive protein binding involved in bundle of His cell-Purkinje myocyte communication GO:0086083 8.62 DSC2 DSG2

Sources for Hidradenitis Suppurativa

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....